Streetbeat News

Stock Prices

LYRA

Lyra Therapeutics shares are trading lower due to the ENLIGHTEN 1 trial failing to meet its primary endpoint. Additionally, Jefferies downgraded LYRA from Buy to Hold and significantly reduced its price target from $10 to $0.5.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 12:23 pm

VALE

UBS analyst Myles Allsop upgrades Vale (NYSE:VALE) from Neutral to Buy and raises the price target from $13 to $15.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 12:22 pm

TBIO

Telesis, trading under the symbol TBIO, announced a 1-for-18 reverse stock split, leading to its shares trading lower.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 12:21 pm

BVS

Bioventus shares surged following the announcement of stronger-than-expected Q1 financial results and an upward revision of its FY24 guidance, surpassing analyst estimates.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 12:20 pm

ALZN

Alzamend Neuro, Inc. (NASDAQ:ALZN) has announced the termination of its at-the-market equity offering program to avoid uncertainty and unfavorable dilution for its stockholders. The program, in partnership with Ascendiant Capital Markets, LLC, will officially end on May 16, 2024, with no further sales of common stock. Through this program, Alzamend raised approximately $1.3 million by selling 1,076,821 shares at an average price of $1.20 per share.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 12:20 pm

GOGO

Gogo's stock price increased following the announcement of their Q1 financial results, which surpassed expectations.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 12:19 pm

HRTX

Heron Therapeutics' stock price increased following the announcement of their Q1 financial results, which exceeded expectations. Additionally, the company has reaffirmed its revenue guidance for FY24.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 12:18 pm

BAND

Bandwidth's shares surged following the announcement of their Q1 financial results, which exceeded expectations. The company also provided optimistic revenue guidance for Q2 and the full year 2024, surpassing analysts' forecasts.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 12:17 pm

MCK

McKesson Corporation (NYSE:MCK) is expected to report Q4 earnings of $6.34 per share, down from $7.19 the previous year, but with projected revenue of $79.32 billion, up from $68.91 billion. The company offers a 0.46% annual dividend yield, equating to $2.48 per share annually. To earn $500 monthly from dividends, an investment of approximately $1,290,319 is needed. McKesson's stock price recently increased by 0.9% to close at $533.41.

Portfolio Pulse from Avi Kapoor

May 07, 2024 | 12:17 pm

BYND

Beyond Meat's shares are trading lower following the announcement of their Q1 financial results, which did not meet expectations.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 12:16 pm